

Meeting details

Subject	86th JPAC meeting
Date	Monday 06 November 2023
Time	09:30 to 12:00
Location	Microsoft Teams

Note: Retrospective comments and subsequent amendments to the minutes are indicated in yellow.

Attendees

Allameddine Allameddine	AA	Medical Director, NIBTS	
Neil Almond	NA	MHRA South Mimms	
Akila Chandrasekar	AC	Chair, SACTCTP	
Ryan Evans	RE	Chair, SACBC	
Tor Hervig	TH	Medical Director, IBTS	
Lisa Jarvis	LJ	Chair, SACTTI	
Chris Jones	CJ	Head of Regulatory Compliance, MHRA	
Lorna McLintock	LM	Medical Director, SNBTS	
Gary Mallinson	GMa	Scientific Lead Safety Policy, JPAC/SaBTO	
Edwin Massey	EM	Medical Director, WBS	
Gail Mifflin	GMi	Chief Medical Officer, NHSBT	
David Olszowka	DO	Regulatory Governance Lead, MHRA	
Peter Rae	PRa	Scientific Publishing Manager, JPAC	(Minutes)
Michelle Ray	MRa	SACBC	
Peter Richardson	PRi	Chair, UK Quality Managers	
Stephen Thomas	ST	Professional Director, JPAC	(Chair)
Angus Wells	AW	Chair, SACCSO	

Apologies

Megan Rowley	MRo	Chair, SACCTM	
Amy Shackell	AS	Regulation Manager, HTA	
Nicole Thornton	NT	Chair, SACIH	

Agenda items

1. Welcome

ST welcomed Michelle Ray, member of SACBC, attending to present item 4.1.

This would be Lisa Jarvis's final JPAC meeting before standing down, and Heli Harvala has been appointed as the new Chair of SACTTI, with the handover taking place before the next EWG meeting.

It is Akila Chandrasekar's intention to stand down as Chair of SACTCTP before the next JPAC meeting, with an interim chair to be sought pending a further review of the remit of the SAC.

Lisa Jarvis and Akila Chandrasekar were thanked for their significant contributions to JPAC and leadership of their SACs over many years.

2. Previous meeting minutes

The minutes of the previous JPAC meeting held on 22 June 2023 (**JPAC 23-58**) were approved.

3. Actions list

A combined EWG/JPAC actions list has been created (**JPAC 23-59**) and open actions pertinent to JPAC were discussed. Actions that were closed since the last meeting were marked with the 'Closed' status for information, to be archived on the 'Closed' tab following the meeting.

- **2015 paper (Washed Red Cells) to be revisited**

Added to SACBC workplan. Action closed.

- **Appointment of Chair of SACIT**

Discussion meetings with stakeholders arranged for w/c 06 and 13 November 2023.

ST

- **Adverse event rate benchmarking**

This will form part of the review into the remit and composition of SACTCTP, following on from the recommendations of the forthcoming JPAC Ways of Working report. Action closed.

- **Clinical supervision at donor sessions**

The publication of previously approved changes to Red Book chapters 4.2 (Staffing and training principles for donation sessions) and 4.3 (Collection of the donation) was paused following responses from stakeholders upon pre-publication of the changes.

To be discussed by SACCS D. Submission for JPAC meeting to be held on 14 March 2024. **AW**

- **Travel criteria for plasmapheresis donors**

Prepared as CN 31-2023. Publication in progress. **PR**

- **Immunosuppression**

Prepared as CN 30-2023. Publication in progress. **PR**

- **42 day red cell validation**

To be discussed at next UK Forum meeting on 01 December 2023. **ST**

- **T antigen testing**

It was noted that the EBA survey has now been completed. **ST** to discuss with **NT**. **ST**

4. SACBC

4.1. Irradiation of Blood Components – Risk Assessment & changes to Red Book (JPAC 23-61)

Proposed amendments to Red Book Chapter 7.31 approved for publication. **PR**

Further discussions are required to explore feasibility of carrying out lymphocyte proliferation studies, with possibility of collaboration with NHSBT Filton and/or Sanquin, Amsterdam. **RE**

5. SACCS D

5.1. Transgender & Non-Binary Donors – Position Statement & changes to WB-DSG/RB (JPAC 23-62)

Position Statement and proposed changes approved for publication pending minor amendments to text for clarity and consistency. It was noted that it would be advantageous for

the WB-DSG and Red Book changes to be prepared for publication by February 2024, to align with anticipated changes to NHSBT's donor registration system.

PR

A review of blood volume estimation as a faint reduction measure (i.e. the assessment of blood volume in transgender and non-binary donors) added to the SACCSO workplan for 2024/25.

AW

5.2. HAV & B19 – changes to WB-DSG (JPAC 23-63)

Approved for publication.

PR

5.3. Acupuncture (JPAC 23-88)

The option appraisal for the definition of acupuncturists as 'qualified practitioners' was discussed but neither option was approved at this meeting, pending further discussion.

Further discussions between JPAC, DHSC and MHRA are required to clarify which body has the authority to authorise any changes and the process for approval.

ST

Engagement with relevant stakeholder groups (e.g. British Acupuncture Federation, British Acupuncture Council) are also required once the options appraisal has been reviewed.

ST

6. SaBTO

A summary report (JPAC 23-66) of SaBTO and working group activities to end of September 2023 was provided. Two particular items were discussed:

6.1. CJD working group

A review of risk reduction measures was previously on hold pending the outcome of experiments on positive Appendix III samples for vCJD risk. However, it has now been decided that the review will go ahead using epidemiological evidence for vCJD risk. The review group, which will include members from UK Blood Services, JPAC, ACDP, UKHSA HFEE, HTA, lay persons and patient advocates, will meet towards the end of the year.

The review group will also look separately at the transmission risk of donations from donors who later develop cerebral amyloid angiopathy (CAA). **GMI** is aware that there are reviews of the recent JAMA paper in other international services including Australia and Canada. She will report back to **GMA** any relevant information or views.

GMI

6.2. Virology subcommittee

The remit of the group will now expand to cover other microbiological risks. An updated workplan is currently being agreed and will be presented to SaBTO.

7. SACTTI

7.1. Residual Risk – Position Statement, September 2023 (updated) (JPAC 23-64)

Approved for publication pending minor amendments.

PR

It was noted that while the residual risk for HBV was known to have risen above 1 in 1 million in 2018, this is not reflected in Figure 1 of the Position Statement. It was suggested this may be the result of calculating aggregated risk across multi-year periods. **LJ** to discuss this with Katy Davison.

LJ

Note: Katy Davison clarified that the peak in HBV incident infections in 2018 was followed by zero infections in 2019, and so while the calculated risk for 2016-2018 was 1.04 per 1 million, this reduced to less than 1 in 1 million when calculated for the 2017-2019 period as shown in Figure 1.

7.2. Human Herpesvirus 8 (HHV-8) – Position Statement, October 2023 (JPAC 23-65)

Approved for publication pending minor amendments.

PR

8. JPAC Office

8.1. Ways of Working review

The final draft of the report has been submitted to the UK Medical Directors, to be discussed later this month ahead of the UK Forum meeting to be held on 01 December 2023.

Following on from the report's recommendations, a review into the scope and composition of SACTCTP is required. Expressions of interest for an interim Chair are being sought as **AC** has previously noted her intention to step down.

ST

Similarly, a plan for the future of SACIT is required with further discussions to be had this week.

ST

8.2. Website refresh project

A business requirements document has been produced following the stakeholder engagement and business analysis carried out by a third party.

New websites for SRI (currently hosted on JPAC website) and SHOT (currently external to JPAC website) are planned to be progressed within this financial year.

The new JPAC website is likely to be developed over subsequent financial years, given the volume of work and cost involved in meeting the specific requirements of the Donor Selection Guidelines site.

8.3. Annexe 1 of the Red Book

The out-of-date list of standards available from MHRA South Mimms Laboratories (formerly NIBSC) previously given on the JPAC website has now been replaced with a signposting link to the [nibsc.org](https://www.nibsc.org) product catalogue.

9. Any other business

9.1. Annual SHOT Report 2022 (available at www.shotuk.org – direct [link](#))

Attendees were asked to note two recommendations from the Report (from ‘Safe systems to ensure safe transfusions’ and ‘Errors related to Information Technology’) which highlight the importance of the work on reconstituting SACIT as discussed previously.

9.2. Thanks given

GMI thanked attendees, and particularly members of the EWG, for the work done ahead of the JPAC meeting to prepare papers for the productive and detailed discussions here.

10. Papers for noting

There were no objections to the papers included on the agenda for noting.